Conditions: Alzheimer Disease
Keywords: antibody immunotherapy
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 494
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Bapineuzumab 0.5 mg/kg
Intervention descriptions: intervention 1: I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.

Protocol document: